[1]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[2]
Ravez, M.S.; Spillier, Q.; Marteau, R.; Feron, O.; Freeick, R.L. Challenges and opportunities in the development of serine synthetic pathway inhibitors for cancer therapy. J. Med. Chem., 2017, 60(4), 1227-1237.
[3]
Kettle, J.G.; Alwan, H.; Bista, M.; Breed, J.; Davies, N.L.; Eckersley, K.; Fillery, S.; Foote, K.M.; Goodwin, L.; Jones, D.R.; Käck, H.; Lau, A.; Nissink, J.W.; Read, J.; Scott, J.S.; Taylor, B.; Walker, G.; Wissler, L.; Wylot, M. Potent and selective inhibitors of MTH1 probe its role in cancer cell survival. J. Med. Chem., 2016, 59(6), 2346-2361.
[4]
Korzhnev, D.M.; Hadden, M.K. Targeting the translesion synthesis pathway for the development of anti-cancer Chemotherapeutics. J. Med. Chem., 2016, 59(20), 9321-9336.
[5]
Heffron, T.P. Small molecule kinase inhibitors for the treatment of brain cancer. J. Med. Chem., 2016, 59(22), 10030-10066.
[6]
Ghislain, I.; Zikos, E.; Coens, C. Health-related quality of life in locally advanced and metastatic breast cancer: Methodological and clinical issues in randomised controlled trials. Lancet Oncol., 2016, 17(7), e294-e304.
[7]
Uttley, L.; Whiteman, B.L.; Woods, H.B.; Harman, S.; Philips, S.T.; Cree, I.A. Building the evidence base of blood-based biomarkers for early detection of cancer: A rapid systematic mapping review. EBioMedicine, 2016, 10, 164-173.
[8]
Hollestelle, A.; VanderBaan, F.H.; Brechuck, A. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 381-401.
[9]
Li, Y.; Li, F.; Jiang, F.; Lv, X.; Zhang, R.; Lu, A.; Zhang, Ge. A mini-review for cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int. J. Mol. Sci., 2016, 17, 1151.
[10]
Sau, S.; Alsaab, H.O.; Kashaw, S.K.; Tatiparti, K.; Iyer, A.K. Small molecule targeting ligand to antibody drug conjugate: A potent regimen for cancer therapy. Drug Discovery. Today, 2017, 22(10), 1547-1556.
[11]
Tatiparti, K.; Sau, S.; Kashaw, S.K.; Iyer, A.K. siRNA Delivery Strategies: A comprehensive review of recent developments. Nanomaterials , 2017, 7(4), 77.
[12]
Sau, S.; Iyer, A.K. Antibody drug conjugate: A new era of targeted cancer therapy. Ann. Pharmacol. Pharm, 2017, 2(5), 1032.
[13]
Kemnitzer, W.; Jiang, S.; Zhang, H.; Kasibhatla, S.; Crogan-Grundy, C.; Blais, C.; Attardo, G.; Denis, R.; Lamothe, S.; Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S.X. Discovery of 4-aryl-2-oxo-2H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. Bioorg. Med. Chem. Lett., 2008, 15(20), 5571-5575.
[14]
Sau, S.; Banerjee, R. Cationic lipid-conjugated dexamethasone as a selective antitumor agent. Eur. J. Med. Chem., 2014, 83, 433-447.
[15]
Sau, S.; Mondal, S.K.; Kashaw, S.K.; Iyer, A.K.; Banerjee, R. Combination of cationic dexamethasone derivative and STAT3 inhibitors (WP1066) for aggressive melanoma: A strategy for repurposing phase I clinical trial drug. Mol. Cell. Biochem., 2017, 436(1-2), 119-136.
[16]
Ursi, P.; Guariento, S.; Trombetti, G.; Orro, A.; Cichero, E.; Milanesi, E.; Fossa, P.; Bruno, O. Further insights in the binding mode of selective inhibitors to human PDE4D enzyme combining docking and molecular dynamics. Mol. Informatics., 2016, 35, 369-381.
[17]
Kumar, B.R.P.; Nanjan, M.J. Comparative molecular similarity indices analysis for predicting the antihyperglycemic activity of thioglitazones. Med. Chem. Res., 2010, 19(8), 1000-1010.
[18]
Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Zhao, J.; Crogan-Grundy, C.; Xu, L.; Lamothe, S.; Gourdeau, H.; Denis, R.; Tseng, B.; Kasibhatla, S.; Cai, S.X. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 3. Structure-activity relationships of fused rings at the 7,8-positions. J. Med. Chem., 2007, 14(12), 2858-2864.
[19]
Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30, 2785-2791.
[20]
GOLD Version 5.2; Cambridge crystallographic data centre: Cambridge,
UK, 2009. .
[21]
Tanchuk1, V.V.Y.; Tanin1, V.O.; Vovk A.I.; Poda G. A new improved hybrid scoring function for molecular docking and scoring based on autodock and autodock. Chem. Biol. Drug Des., 2016, 87, 618-625.
[22]
Yu, V.; Tanchuk, V.; Tanin, A.I.V.; Poda, G. A New scoring function for molecular docking based on autodock and autodock vina. Curr. Drug Dis. Technol., 2015, 12, 170-178.
66
9
1